Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Daiichi Sankyo's anti-infective business
|
| gptkbp:ceo |
Isao Teshirogi
|
| gptkbp:clinical_trial |
pain relief medications
phase I trials phase II trials phase III trials COVID-19 treatments HIV treatments |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:employees |
approximately 5,000
|
| gptkbp:founded |
1878
|
| gptkbp:founder |
Taikichiro Shiono
|
| gptkbp:global_presence |
over 20 countries
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shionogi & Co., Ltd.
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:innovation |
drug discovery
vaccine development biologics development |
| gptkbp:invention |
over 1,000 patents filed
|
| gptkbp:location |
gptkb:Japan
|
| gptkbp:market_cap |
$6 billion (2021)
|
| gptkbp:marketed_as |
gptkb:Cymbalta
gptkb:Duloxetine gptkb:Oseltamivir S-1 Loxonin Rivastigmine |
| gptkbp:partnership |
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer |
| gptkbp:philanthropy |
education programs
healthcare initiatives |
| gptkbp:products |
antibiotics
antiviral drugs pain relief medications |
| gptkbp:regulatory_compliance |
FDA approved drugs
EMA approved drugs |
| gptkbp:research |
Dr. Yoshihiro Matsumoto
|
| gptkbp:research_focus |
infectious diseases
pain management |
| gptkbp:revenue |
$1.5 billion (2020)
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
Shionogi Pharma, Inc.
|
| gptkbp:sustainability_initiatives |
social responsibility
environmental responsibility governance practices |
| gptkbp:website |
www.shionogi.com
|
| gptkbp:bfsParent |
gptkb:Xofluza
|
| gptkbp:bfsLayer |
6
|